Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 20/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188543 | 0.85 | MAP2K2 (0.67) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL30220932 | 0.85 | MAP2K2 (0.67) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL4584404 | 0.84 | MAP2K2 (0.57) | MAP2K2MAP2K1BRAF | |
| SCHEMBL3262393 | 0.80 | MAP2K2 (0.72) | MAP2K2MAP2K1BRAF | |
| SCHEMBL29413608 | 0.76 | MAP2K2 (0.66) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL1488518 | 0.76 | MAP2K2 (0.66) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL1488201 | 0.75 | MAP2K2 (0.71) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL29413428 | 0.75 | MAP2K2 (0.71) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL29413639 | 0.75 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 | |
| SCHEMBL189265 | 0.75 | MAP2K2 (0.80) | MAP2K2MAP2K1BRAFMAPK1MAP2K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2056829-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | Exelixis, Inc. (US) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008021389-A2 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |